Editas Retained Earnings from 2010 to 2025

EDIT Stock

USD 1.30 0.09 6.47%

Editas Medicine Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Editas Medicine retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2014-12-31

Previous Quarter

-1.4 B

Current Value

-1.5 B

Quarterly Volatility

433.9 M

Yuan Drop

Covid

Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 3 M or Selling General Administrative of 59.8 M, as well as many indicators such as Price To Sales Ratio of 3.07, Dividend Yield of 0.0 or PTB Ratio of 0.61. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.

Check out the analysis of Editas Medicine Correlation against competitors.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Latest Editas Medicine's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Editas Medicine over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Editas Medicine's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (1.47 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Editas Retained Earnings Regression Statistics

	Arithmetic Mean	(516,472,741)
	Geometric Mean	106,290,300
	Coefficient Of Variation	(103.69)
	Mean Deviation	453,719,083
	Median	(305,850,000)
	Standard Deviation	535,548,198
	Sample Variance	286811.9T
	Range	1.5B
	R-Value	(0.96)
	Mean Square Error	26185.8T
	R-Squared	0.91
	Slope	(107,588,223)
	Total Sum of Squares	4302178.1T

Editas Retained Earnings History

	2025	-1.4 B
	2024	-1.5 B
	2023	-1.2 B
	2022	-1.1 B
	2021	-857.7 M
	2020	-665.2 M
	2019	-549.2 M

Other Fundumenentals of Editas Medicine

Retained Earnings Total Equity

Editas Medicine Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Common Stock	Short Term Investments	Capital Surpluse	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.82	-0.72	0.86	0.73	0.99	0.6	0.93	0.62	0.83	0.3	0.91	0.74	0.84	0.66	0.96	0.86	-0.6	0.63	0.49	0.69	0.52
Total Stockholder Equity	0.95		-0.8	-0.66	0.81	0.47	0.9	0.49	0.93	0.57	0.64	0.22	0.8	0.54	0.8	0.63	0.93	0.83	-0.51	0.76	0.56	0.8	0.5
Net Debt	-0.82	-0.8		0.53	-0.71	-0.53	-0.84	-0.81	-0.8	-0.84	-0.66	-0.14	-0.74	-0.59	-0.53	-0.44	-0.76	-0.67	0.49	-0.41	-0.5	-0.36	-0.31
Retained Earnings	-0.72	-0.66	0.53		-0.79	-0.58	-0.68	-0.31	-0.82	-0.18	-0.65	-0.84	-0.85	-0.58	-0.82	-0.93	-0.7	-0.92	0.89	-0.19	0.12	-0.46	-0.92
Accounts Payable	0.86	0.81	-0.71	-0.79		0.65	0.82	0.56	0.83	0.54	0.77	0.45	0.84	0.69	0.87	0.73	0.79	0.87	-0.59	0.42	0.13	0.62	0.62
Total Liab	0.73	0.47	-0.53	-0.58	0.65		0.8	0.61	0.56	0.49	0.91	0.34	0.8	0.88	0.62	0.48	0.66	0.6	-0.56	0.12	0.15	0.19	0.38
Total Current Assets	0.99	0.9	-0.84	-0.68	0.82	0.8		0.69	0.89	0.66	0.86	0.26	0.92	0.77	0.78	0.6	0.95	0.81	-0.61	0.54	0.5	0.57	0.46
Property Plant Equipment	0.6	0.49	-0.81	-0.31	0.56	0.61	0.69		0.48	0.83	0.71	0.02	0.64	0.68	0.37	0.14	0.55	0.38	-0.37	0.01	0.23	-0.04	0.04
Net Tangible Assets	0.93	0.93	-0.8	-0.82	0.83	0.56	0.89	0.48		0.51	0.71	0.44	0.88	0.61	0.83	0.83	0.9	0.95	-0.66	0.6	0.35	0.7	0.72
Current Deferred Revenue	0.62	0.57	-0.84	-0.18	0.54	0.49	0.66	0.83	0.51		0.62	-0.12	0.49	0.6	0.32	0.09	0.52	0.35	-0.16	0.28	0.45	0.22	-0.05
Long Term Debt	0.83	0.64	-0.66	-0.65	0.77	0.91	0.86	0.71	0.71	0.62		0.34	0.83	0.98	0.8	0.57	0.69	0.72	-0.55	0.27	0.16	0.36	0.48
Net Receivables	0.3	0.22	-0.14	-0.84	0.45	0.34	0.26	0.02	0.44	-0.12	0.34		0.55	0.31	0.48	0.75	0.3	0.6	-0.85	-0.24	-0.52	0.11	0.84
Deferred Long Term Liab	0.91	0.8	-0.74	-0.85	0.84	0.8	0.92	0.64	0.88	0.49	0.83	0.55		0.74	0.79	0.73	0.92	0.87	-0.82	0.29	0.18	0.43	0.64
Short Long Term Debt	0.74	0.54	-0.59	-0.58	0.69	0.88	0.77	0.68	0.61	0.6	0.98	0.31	0.74		0.75	0.48	0.58	0.61	-0.49	0.2	0.12	0.28	0.41
Short Term Debt	0.84	0.8	-0.53	-0.82	0.87	0.62	0.78	0.37	0.83	0.32	0.8	0.48	0.79	0.75		0.8	0.74	0.88	-0.58	0.54	0.13	0.72	0.73
Common Stock	0.66	0.63	-0.44	-0.93	0.73	0.48	0.6	0.14	0.83	0.09	0.57	0.75	0.73	0.48	0.8		0.63	0.94	-0.72	0.32	-0.09	0.56	0.97
Short Term Investments	0.96	0.93	-0.76	-0.7	0.79	0.66	0.95	0.55	0.9	0.52	0.69	0.3	0.92	0.58	0.74	0.63		0.82	-0.65	0.58	0.5	0.63	0.48
Capital Surpluse	0.86	0.83	-0.67	-0.92	0.87	0.6	0.81	0.38	0.95	0.35	0.72	0.6	0.87	0.61	0.88	0.94	0.82		-0.71	0.47	0.13	0.66	0.86
Long Term Debt Total	-0.6	-0.51	0.49	0.89	-0.59	-0.56	-0.61	-0.37	-0.66	-0.16	-0.55	-0.85	-0.82	-0.49	-0.58	-0.72	-0.65	-0.71		0.07	0.13	-0.15	-0.74
Net Invested Capital	0.63	0.76	-0.41	-0.19	0.42	0.12	0.54	0.01	0.6	0.28	0.27	-0.24	0.29	0.2	0.54	0.32	0.58	0.47	0.07		0.76	0.9	0.18
Net Working Capital	0.49	0.56	-0.5	0.12	0.13	0.15	0.5	0.23	0.35	0.45	0.16	-0.52	0.18	0.12	0.13	-0.09	0.5	0.13	0.13	0.76		0.46	-0.26
Long Term Investments	0.69	0.8	-0.36	-0.46	0.62	0.19	0.57	-0.04	0.7	0.22	0.36	0.11	0.43	0.28	0.72	0.56	0.63	0.66	-0.15	0.9	0.46		0.45
Capital Stock	0.52	0.5	-0.31	-0.92	0.62	0.38	0.46	0.04	0.72	-0.05	0.48	0.84	0.64	0.41	0.73	0.97	0.48	0.86	-0.74	0.18	-0.26	0.45

Click cells to compare fundamentals

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-1.5 B	-1.4 B
Retained Earnings Total Equity	-970.3 M	-921.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC